Delivery Order SPE2DB25D3404-SPE2DB25FUQHE
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $94,011.78 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product. This is a firm fixed price delivery order issued on September 8, 2025, with an ultimate completion date of September 9, 2025, and represents a non-competitive set-aside contract. The award will be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate office and...
- The Defense Logistics Agency awarded a $50,801.12 delivery order to AmerisourceBergen Drug Corp on July 23, 2025, for the supply of SKYRIZI 150 mg/mL pen/mL, a pharmaceutical product used to treat inflammatory conditions. This is a firm fixed-price contract with no set-aside designation, competitively awarded to the prime contractor. The order is scheduled for completion by July 24, 2025, with performance based in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of SKYRIZI 150 MG/ML PenML, a pharmaceutical product, with a ceiling value of $26,166.64. This competitively awarded, firm fixed-price delivery order is set to conclude on August 19, 2025, and will be fulfilled from the vendor's facility in Conshohocken, Pennsylvania. The contract represents a continuation of AmerisourceBergen's role as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $61,540.45 to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen, a pharmaceutical product. This non-competitive, firm fixed price delivery order was executed on September 3, 2025, with an ultimate completion date of September 4, 2025, and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a single-line item delivery against AmerisourceBergen's existing federal...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $42,722.77 by the Defense Logistics Agency on July 21, 2025, for the supply of SKYRIZI 150 mg/ml pen milliliter pharmaceutical product. The contract is designated as firm fixed price with no set-aside provision and carries an ultimate completion date of July 22, 2025. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,788.01 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen/ml on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price delivery order represents a non-competitive award issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through December...
- The Defense Logistics Agency awarded a $36,212.07 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 MG/ML pen/mL, a specialty pharmaceutical product. This competitively awarded, firm fixed-price delivery order was issued on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting the company's demonstrated...
- The Defense Logistics Agency awarded a $20,990.24 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of SKYRIZI 150 mg/ml pen/ml, a pharmaceutical product to be delivered to the company's facility in Conshohocken, Pennsylvania. This firm fixed-price delivery order represents a non-competitive set-aside contract and is scheduled for completion by September 5, 2025. The award leverages AmerisourceBergen's existing Indefinite Delivery Contract (IDC) vehicle with...
- The Defense Logistics Agency awarded a $41,824.89 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/ml pen medication on September 2, 2025, with completion expected by September 3, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract action under a larger procurement vehicle. This delivery order...
- The Defense Logistics Agency awarded a $89,511.22 delivery order to AmerisourceBergen Drug Corp for SKYRIZI 150 mg/mL pen/mL pharmaceutical products on September 2, 2025, with completion scheduled for September 3, 2025. This firm fixed price contract is non-set-aside and utilizes AmerisourceBergen's existing indefinite delivery contract vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate...
- SPE2DB25D3404Indefinite Delivery Contract
- SPE2DB25D3404-SPE2DB25FUQHEDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $26,546.03 to AmerisourceBergen Drug Corp for the supply of SKYRIZI 150 mg/ml pen, a pharmaceutical product. This firm fixed-price contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a non-competitive delivery order issued without set-aside designation. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters and primary operations center. This delivery order falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This comprehensive vehicle enables the contractor to supply pharmaceutical products and medical supplies supporting military healthcare programs globally. AmerisourceBergen's extensive federal contract portfolio demonstrates its role as a critical pharmaceutical distributor for the Defense Health Agency and other federal healthcare systems, consistently fulfilling requirements through open competition across a diverse range of therapeutic domains and product categories.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.5k | 9/10/25 |